A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
AGENUS INC operates in the Biological Products, (No Diagnostic Substances) industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 114M | 114M | - | 156M | - | 296M |
| Net Income | -101K | -101K | -227M | -246M | -220M | -24M |
| EPS | $0.00 | $0.00 | $-10.59 | $-275.00 | $-15.31 | $-2.16 |
| Free Cash Flow | -77M | -77M | -159M | -234M | -228M | -24M |
| ROIC | -7.0% | -8.9% | -53.2% | -50.8% | -43.4% | 74.8% |
| Gross Margin | 99.1% | 99.1% | - | 98.0% | - | 98.8% |
| Debt/Equity | 0.00 | -0.37 | -0.11 | -0.08 | -0.22 | 0.41 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -20M | -20M | -120M | -160M | -179M | 26M |
| Operating Margin | -17.7% | -17.7% | - | -102.1% | - | 8.7% |
| ROE | 0.0% | - | - | - | - | -70.1% |
| Shares Outstanding | 38M | 38M | 21M | 1M | 14M | 11M |
AGENUS INC passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 98.6%.
AGENUS INC (AGEN) has a 5-year average return on invested capital (ROIC) of -16.3%. This is below average and may indicate limited pricing power.
AGENUS INC (AGEN) has a market capitalization of $181M. It is classified as a small-cap stock.
AGENUS INC (AGEN) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.05%.
AGENUS INC (AGEN) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
AGENUS INC (AGEN) reported annual revenue of $114 million in its most recent fiscal year, based on SEC EDGAR filings.
AGENUS INC (AGEN) has a net profit margin of -0.1%. The company is currently unprofitable.
AGENUS INC (AGEN) generated $-77 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
AGENUS INC (AGEN) has a 5-year average gross margin of 98.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for AGENUS INC (AGEN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AGENUS INC (AGEN) has a book value per share of $-7.06, based on its most recent annual SEC filing.